Zai Lab (ZLAB) said late Wednesday the US Food and Drug Administration has granted orphan drug designation to ZL-1310 for the treatment of small cell lung cancer following data from an ongoing phase 1a/1b study.
ZL-1310 will be eligible for certain development incentives, including tax credits for certain clinical trials and the potential to receive a seven-year US market exclusivity period upon product approval, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。